Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | LSS | P48449 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | GBA1 | P04062 | 4/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9406324 | 1.00 | CYP1A2 (0.45) | CYP1A2HTTLMNAMAPK1PKM | |
| SCHEMBL17431971 | 1.00 | CYP1A2 (0.45) | CYP1A2HTTLMNAMAPK1PKM | |
| SCHEMBL12675265 | 1.00 | CYP1A2 (0.45) | CYP1A2HTTLMNAMAPK1PKM | |
| SCHEMBL9406316 | 1.00 | CYP1A2 (0.45) | CYP1A2HTTLMNAMAPK1PKM | |
| SCHEMBL9406573 | 0.98 | CYP1A2 (0.43) | CYP1A2HTTLMNAMAPK1PKM | |
| SCHEMBL9406587 | 0.98 | CYP1A2 (0.43) | CYP1A2HTTLMNAMAPK1PKM | |
| SCHEMBL9406580 | 0.98 | CYP1A2 (0.43) | CYP1A2HTTLMNAMAPK1PKM | |
| SCHEMBL9406547 | 0.98 | CYP1A2 (0.43) | CYP1A2HTTLMNAMAPK1PKM | |
| SCHEMBL9406554 | 0.98 | CYP1A2 (0.43) | CYP1A2HTTLMNAMAPK1PKM | |
| SCHEMBL9406542 | 0.98 | CYP1A2 (0.43) | CYP1A2HTTLMNAMAPK1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2199270-B1 | LIQUID CRYSTALLINE COMPOUND, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORP (JP) | 2016-05-25 | — | — | EP | disclosed |
| US-8580142-B2 | Liquid crystal compound, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2013-11-12 | — | — | US | disclosed |
| US-20100328600-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2010-12-30 | — | — | US | disclosed |
| EP-2199270-A1 | LIQUID CRYSTALLINE COMPOUND, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT | Chisso Corporation (JP) | 2010-06-23 | — | — | EP | disclosed |
| EP-0355552-B1 | Alkoxymethyl- and alkenyloxymethyl-cyclohexanes | HOFFMANN LA ROCHE (CH) | 1994-02-23 | — | — | EP | disclosed |
| US-5102578-A | Electrooptics | HOFFMANN-LA ROCHE INC. (US) | 1992-04-07 | — | — | US | disclosed |
| EP-0355552-A2 | Alkoxymethyl- and alkenyloxymethyl-cyclohexanes | F. HOFFMANN-LA ROCHE AG (CH) | 1990-02-28 | — | — | EP | disclosed |
| WO-1989011496-A1 | SIDE-CHAIN POLYMERS | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1989-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100328600-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | KIF23, MARK3, CCND3 | CYP1A2 3613/4885HTT 1890/4885LMNA 2081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.